Mandatory warning sign policies were not associated with reduced cannabis use during pregnancy, nor did they shift opinions regarding risk among those using cannabis prior to pregnancy.
At this point, the medical use of cannabis is legal in 37 states and the District of Columbia (D.C.). The recreational use of cannabis has been legalized in 21 states and D.C. The downstream effect [...]
A large cohort study from Canada has observed that cannabis use during pregnancy was associated with increased risk of preterm birth, low birth weight and small-for-gestational age.
Opioid use during pregnancy co-occurs with other variables that are associated with worse outcomes in children, specifically maternal depression and the use of alcohol, tobacco, and other drugs.
Prenatal cannabis exposure was associated with persisting vulnerability to psychopathology throughout early adolescence.
Prenatal opioid use is associated with increased maternal and infant mortality, prematurity, and poor neonatal outcomes.
Cannabis use, as well as use of benzodiazepines and sedative-hypnotic medications, was more common in women with depression.
It is essential that clinicians, as well as those working in dispensaries, must educate women about the risks associated with cannabis use during pregnancy.
Parenting support, maternal bonding with the infant, engagement in an OUD treatment program, and recovery-specific support systems promoted recovery in postpartum women with opioid use disorders.
Screening, Brief Intervention and Referral to Treatment or SBIRT has been shown to be a quick and effective means of identifying and intervening with patients whose patterns of use put them at risk for, or who already have, substance-related health problems.
